Drugs and Devices

FDA approves Nulojix for prevention of acute rejection in kidney transplant patients

The U.S. Food and Drug Administration (FDA) has approved Nulojix (belatacept) for prevention of acute rejection in adult patients who have had a kidney transplant. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Newsletter Subscribe

  • This field is for validation purposes and should be left unchanged.

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing

Shares